Cytokinetics (NASDAQ:CYTK) used its 2026 annual meeting of stockholders to review a year that executives described as a major transition for the company, highlighted by the approval and launch of MYQORZO for adults with symptomatic obstructive hypertrophic cardiomyopathy, or oHCM.
Robert Blum, Cytokinetics’ President and Chief Executive Officer, said 2025 “represented a major inflection point” for the company and marked the culmination of years of research in muscle biology. MYQORZO received its first FDA approval in 2025 for adults with symptomatic oHCM, and Blum said the drug was also approved in China in 2025 and in Europe in early 2026.
Stockholders Approve Board Nominees and Other Proposals
Jeff Hessekiel, Executive Vice President, Chief Legal and Administrative Officer, conducted the formal portion of the meeting. Stockholders approved the reelection of three Class I directors: Ed Kaye, Wendell Wierenga and Nancy Wysenski. Each will serve until the company’s 2029 annual meeting.
Stockholders also approved an amendment and restatement of Cytokinetics’ amended and restated 2015 Employee Stock Purchase Plan, increasing the number of authorized shares reserved for issuance under the plan by 1 million shares, from 1,459,879 to 2,459,879.
In addition, stockholders ratified the appointment of Ernst & Young LLP as the company’s independent registered accounting firm for the fiscal year ending Dec. 31, 2026. They also approved, on an advisory basis, the compensation of the company’s named executive officers.
MYQORZO Launch Metrics and Market Access
Blum said Cytokinetics has focused its U.S. commercial efforts on high-volume cardiac myosin inhibitor prescribers, which the company refers to as “velocity accounts.” He said roughly 700 physicians and offices account for about 80% of cardiac myosin inhibitor volume to date, and that about 90% of them had been detailed by the company’s sales force through the first nine weeks of commercialization.
As of March 31, Blum said 275 prescribers had prescribed MYQORZO, representing penetration into about 50% of the company’s high-volume target accounts. He also said 680 patients had been prescribed MYQORZO as of March 31, with those numbers increasing in the second quarter.
Blum said Cytokinetics is working toward broader market access, including a goal of nearly 90% coverage of Medicare lives in the second quarter and 50% of commercial lives covered in the third quarter. He said the company expects “parity access” among commercial accounts by the end of the year.
Pipeline Progress in HCM and Heart Failure
Beyond the commercial launch, Cytokinetics highlighted progress in its pipeline of muscle-directed therapies. Blum said the company presented primary results in 2025 from MAPLE-HCM, a Phase III trial evaluating aficamten as monotherapy compared with metoprolol in patients with oHCM. The results were also published in The New England Journal of Medicine. Blum said the trial showed aficamten improved exercise capacity, while metoprolol had a detrimental effect.
The company also reported recent top-line results from ACACIA-HCM, a pivotal Phase III trial of aficamten in non-obstructive HCM, or nHCM. Blum said the trial demonstrated statistically significant improvements from baseline to week 36 in both dual primary endpoints: KCCQ clinical summary score and peak VO2, each compared with placebo. He described the findings as “encouraging, persuasive, and compelling” and said Cytokinetics hopes to present full data with a concurrent publication, potentially as soon as late August.
Blum said Cytokinetics plans to engage the FDA around both a supplemental new drug application accepted for filing based on MAPLE and a potential supplemental filing based on ACACIA results.
In heart failure, Blum said Cytokinetics continues to enroll COMET-HF, a Phase III trial of omecamtiv mecarbil in patients with heart failure with severely reduced ejection fraction. He said the study recently expanded enrollment to include China, in addition to ongoing enrollment in North America and Europe.
The company is also advancing AMBER-HFpEF, a Phase II trial of ulacamten in patients with heart failure and preserved ejection fraction. Blum said Cytokinetics recently expanded cohort 1 of the study to enroll more patients as it considers potential later-stage development.
Balance Sheet and 2026 Priorities
Blum said Cytokinetics ended the first quarter with approximately $1.1 billion in cash and cash equivalents. He also said the company recently completed a public offering that generated approximately $760 million in net proceeds, bringing pro forma cash to roughly $1.8 billion entering the second quarter.
Blum said the capital will support the launch of MYQORZO, continued pipeline advancement and ongoing research and development. He also reiterated the company’s Vision 2030 objectives, including ambitions to reach at least 100,000 patients across 15 countries through direct operations in North America and Europe and through partners in Japan, China and the rest of the world.
John Henderson, Chairman of Cytokinetics’ Board of Directors, closed the meeting by saying 2025 was a “transformational year” that cemented Cytokinetics as a global commercial biopharmaceutical company, with MYQORZO underway in the U.S. and expected soon in Europe.
About Cytokinetics (NASDAQ:CYTK)
Cytokinetics, Inc is a late?stage biopharmaceutical company focused on the discovery and development of novel small?molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
